Payment overview · 2025
General Payments
$193.78
6 reported records · 4 companies
Healthcare provider profile · identity verified
Ashley Dawn Logan, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ALBANY, KY · NPI 1386064228
Verified facts
What the public records show
CMS Open Payments records show Ashley Dawn Logan, APRN received $193.78 in general payments during 2025 across 6 reported records.
Melinta Therapeutics, LLC accounted for 56.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $108.75 | 56.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.62 | 28.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.69 | 8.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.72 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $193.78 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $108.75 | 1 | 2025 |
Source payment records
|
|||||
| Vabomere Normalized: vabomere |
Drug | Melinta Therapeutics, LLC | $108.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.62 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 584 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 26 |
| Lisinopril | Lisinopril | 196 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 30 |
| Alprazolam | Alprazolam | 161 | 11 |
| Atorvastatin Calcium | Atorvastatin Calcium | 143 | 25 |
| Omeprazole | Omeprazole | 143 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 23 |
| Gabapentin | Gabapentin | 118 | suppressed |
| Lorazepam | Lorazepam | 107 | suppressed |
| Furosemide | Furosemide | 106 | 18 |
| Meloxicam | Meloxicam | 103 | 14 |
| Metformin Hcl | Metformin Hcl | 103 | 17 |
| Diazepam | Diazepam | 100 | suppressed |
| Potassium Chloride | Potassium Chloride | 87 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 36 |
| Atenolol | Atenolol | 79 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 73 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 72 | 16 |
| Simvastatin | Simvastatin | 68 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 16 |
| Ondansetron Odt | Ondansetron | 61 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 58 | suppressed |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Pregabalin | Pregabalin | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | 11 |
| Prednisone | Prednisone | 52 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 11 |
| Promethazine Hcl | Promethazine Hcl | 51 | 14 |
| Sertraline Hcl | Sertraline Hcl | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Amoxicillin | Amoxicillin | 45 | 11 |
| Azithromycin | Azithromycin | 45 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Losartan Potassium | Losartan Potassium | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 11 |
| Eliquis | Apixaban | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 12 |
| Famotidine | Famotidine | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Trulance | Plecanatide | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $193.78 · 6 records | Melinta Therapeutics, LLC | BREZTRI, PAXLOVID, Rezzayo, VRAYLAR, Vabomere | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error